We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01507727
Recruitment Status : Unknown
Verified January 2012 by Jiangsu HengRui Medicine Co., Ltd..
Recruitment status was:  Recruiting
First Posted : January 11, 2012
Last Update Posted : January 11, 2012
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:
This drug has been developed to treat Hyponatremia. The primary purpose of this study is to verify the efficacy and safety of seven-day repeated oral administration of tolvaptan at 15, 30, and 60 mg or placebo in patients with Non-hypovolemic Non-acute Hyponatremia secondary to Congestive Heart Failure (CHF), hepatic cirrhosis or Syndrome of Inappropriate Antidiuretic Hormone (SIADH), despite receiving standard therapy. This study is being conducted in China.

Condition or disease Intervention/treatment Phase
Non-hypovolemic Non-acute Hyponatremia Drug: Tolvaptan Drug: Placebo Phase 2 Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled (Standard Therapy + Placebo) Study to Evaluate the Efficacy and Safety of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
Study Start Date : January 2012
Estimated Primary Completion Date : September 2012
Estimated Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Tolvaptan
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Drug: Tolvaptan Drug: Tolvaptan
Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
Placebo Comparator: Drug: Placebo Drug: Placebo
placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.


Outcome Measures

Primary Outcome Measures :
  1. The change of average daily Area Under the Curve (AUC) of serum sodium by day 4 and 7 comparing with baseline serum sodium level within the double-blind therapy period [ Time Frame: 4 and 7 days ]

Secondary Outcome Measures :
  1. Percentage of patients with normalized serum sodium at Day 4 [ Time Frame: 4 day ]
  2. Percentage of patients with normalized serum sodium at Day 7 [ Time Frame: 7 day ]
  3. Time to first normalization in serum sodium [ Time Frame: up to 7 days ]
  4. Change from baseline in serum sodium at Day 4 [ Time Frame: 4 day ]
  5. Change from baseline in serum sodium at Day 7 [ Time Frame: 7 day ]
  6. Percentage of patients requiring fluid restriction at any time during the double-blind therapy period of the study [ Time Frame: up to 7 days ]
  7. 24-hour urine output [ Time Frame: day 1, day 2, day 3, day 4, day 5, day 6 and day 7 ]
  8. Change from baseline in body weight (hypervolemic patients only) [ Time Frame: day 1, day 2, day 3, day 4, day 5, day 6 and day 7 ]
  9. Fluid balance (hypervolemic patients only) [ Time Frame: day 1, day 2, day 3, day 4, day 5, day 6 and day 7 ]
  10. The percentage of patients who are designated as treatment failure due to the need for saline infusion, with or without fluid restriction [ Time Frame: up to 7 days ]
  11. For CHF patients, improvement of symptoms and relevant physical examination measures [ Time Frame: day 1, day 2, day 3, day 4, day 5, day 6 and day 7 ]
  12. For hepatic edema patients, improvement of symptoms and relevant physical examination measures or ultrasound test findings [ Time Frame: day 1, day 2, day 3, day 4, day 5, day 6 and day 7 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (for CHF):

  1. Patients with CHF who exhibit edema, jugular venous distention, hepatomegaly, or pulmonary congestion.
  2. Non-hypovolemic and Non-acute hyponatremia with a serum sodium < 135mEq/L before randomization.
  3. Patients who have taken furosemide at 40 mg/d or more (oral dosing) without alteration of dosage for the 3 days of the observation period.
  4. Patients whose body weight has been stable (±1.0 kg) for 2 days prior to commencement of study drug administration.
  5. Age:18~80 (when informed consent is obtained),male or female.
  6. In-patient subjects.
  7. Informed consent.

Inclusion Criteria (for hepatic cirrhosis):

  1. Patients with hepatic edema.
  2. Non-hypovolemic and non acute hyponatremia with a serum sodium < 135mEq/L before randomization.
  3. Age:18~65 (when informed consent is obtained),male or female.
  4. In-patient subjects.
  5. Informed consent.

Inclusion Criteria (for SIADH and others):

  1. Patients with SIADH arising from a variety of etiologies.
  2. Non-hypovolemic and non acute hyponatremia with a serum sodium < 135mEq/L before randomization.
  3. Age:18~80 (when informed consent is obtained),male or female.
  4. In-patient subjects.
  5. Informed consent.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01507727


Contacts
Contact: Fusheng Wang, PhD fswang@public.bta.net.cn
Contact: Lin Zhu 051885475957 acetone_zhulin@yahoo.com.cn

Locations
China
Cardiology, Beijing An Zhen Hospital Affiliated to Capital University of Medical Science Recruiting
Beijing, China
Contact: Suo    010-64456464      
Principal Investigator: Changsheng Ma, PhD         
Endocrinology, Beijing Friendship Hospital Recruiting
Beijing, China
Contact: Liu    010-84205645      
Principal Investigator: Wenying Yang, PhD         
Hepatology, No. 302 Hospital Recruiting
Beijing, China
Contact: Yu    010-63879892      
Principal Investigator: Fusheng Wang, PhD         
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Beijing 302 Hospital
Beijing Anzhen Hospital
Beijing Friendship Hospital
More Information

Responsible Party: Jiangsu HengRui Medicine Co., Ltd.
ClinicalTrials.gov Identifier: NCT01507727     History of Changes
Other Study ID Numbers: HENGRUI20111231
First Posted: January 11, 2012    Key Record Dates
Last Update Posted: January 11, 2012
Last Verified: January 2012

Keywords provided by Jiangsu HengRui Medicine Co., Ltd.:
hyponatremia
Non-hypovolemic and Non-acute hyponatremia
Tolvaptan

Additional relevant MeSH terms:
Hyponatremia
Water-Electrolyte Imbalance
Metabolic Diseases
Tolvaptan
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs